How to track CRO commitments, change orders and invoices

Most CRO budget surprises don't start with an invoice. They start with a commitment nobody had a full view of: a change order approved by the study team, a SOW extended by three months, a pass-through budget that quietly grew.

And change is the norm, not the exception. A 2024 Tufts CSDD study of 950 clinical trial protocols found that 76% had at least one protocol amendment, and such amendments can result in changes to CRO scope, timelines and costs. Meanwhile, the accounting system only shows what has been invoiced so far.

I previously worked in finance at an early-stage biotech, where contracts, change orders, purchase orders and invoices lived in different files and systems. Getting a reliable picture of our total commitments meant piecing it together by hand. This guide focuses on the practical challenges of tracking contract values, managing change orders, avoiding double-counted purchase orders and reviewing CRO invoices in context.

1. Start with the contract, not the invoice

The value of a CRO engagement is defined by its SOWs and change orders, not by the invoices that follow. The problem is rarely that these records are wrong. It is that they live in different places: the latest SOW with Clinical Operations, contract values in a finance spreadsheet, invoices in the accounting system. Each record is correct, yet nobody can quickly answer: What is our current financial exposure to this CRO?

So start by recording the value of each SOW, its currency, payment structure, programme and owner. Then connect change orders, purchase orders and invoices to it.

2. Track change orders by status

Make the financial impact of a change visible as soon as it is proposed, not when it has been signed. Use at least these statuses:

• Proposed: submitted by the CRO, not yet approved
• Under review: being evaluated for scope, pricing and budget impact
• Approved: signed and formally executed
• Rejected or withdrawn

Example

A biotech signs a €480,000 SOW. After three months, €120,000 has been invoiced. The SOW then receives an approved change order of €45,000, and the CRO proposes a further €30,000 change that is still under review.

The accounting system shows €120,000. Management needs to see €405,000 approved and not yet invoiced, plus €30,000 in proposed changes that could otherwise quietly become a budget overrun.

Two things to check on every change order

Are the rates consistent with the original agreement? If a monitoring visit was priced at €1,800 in the SOW and appears at €2,200 in a change order, there should be a clear explanation. Rate changes can be justified, but they should be approved explicitly, not accepted by default. Keep the original budget at hand as your baseline.

Is it retroactive? CROs sometimes submit change orders for work that has already been performed. That is not always unreasonable, but it means you lost the chance to approve the cost before it was incurred. If it happens repeatedly, agree on a process with the CRO for flagging out-of-scope work before it starts.

3. Don't double-count purchase orders

Many biotechs issue purchase orders to authorise CRO spend. But a PO issued under an existing contract is not a new commitment. If your €525,000 contract is already in your commitment overview, a €525,000 PO covering the same scope does not add another €525,000 of exposure. Count both, and your commitments double.

Treat contracts and POs as linked records:

• The contract defines what you have agreed to pay.
• The PO defines what has been authorised internally, and is used to check incoming invoices.

A PO is a new commitment when it authorises work not covered by any existing agreement. The point is to identify overlapping scope, not to add up every document.

A small biotech does not need a procurement department for this. A simple approval process with clear authority limits is usually enough.

4. Review CRO invoices against the contract

A CRO invoice can be arithmetically correct and still be wrong: it may bill for work that was never authorised, a milestone that hasn't been reached, or a change order still under negotiation. Beyond standard invoice controls, check:

1. Scope: Is the work covered by the SOW or an approved change order?
2. Rates: Do the prices match the original budget or approved change order?
3. Milestone: Has the billing event actually occurred? Confirm with the study owner.
4. Pass-through costs: Are third-party costs documented and within agreed limits?

A fixed-fee milestone contract needs different checks than a time-and-materials agreement, but the principle is the same: review the invoice against what was agreed and what has actually happened, not just against what the supplier has billed.

5. Remaining contract value is not an accrual, and not a cash forecast

Remaining contract value is a management measure, not an accrual and not necessarily a legal liability. An accrual reflects work that has been performed. Remaining contract value reflects work that has been agreed. Part of it may already be performed and need accruing; the rest may not happen for a year or more, or may change under the contract's termination terms.

Neither is a cash forecast. For runway planning, you also need payment terms, milestone timing and expected scope changes. Commitment tracking supports financial planning; it does not replace accrual accounting or cash-flow forecasting.

6. Hold a 20-minute monthly CRO review

Commitment visibility is most useful when it is maintained continuously, not rebuilt the week before a board meeting. A short monthly review between finance and the relevant R&D or Clinical Operations owner is enough for most small biotechs. For each major CRO, go through:

• Contract position: original value, approved and proposed change orders, changes to scope or timelines
• Spend position: invoiced to date, remaining value, invoices on hold
• Looking ahead: upcoming milestones, work performed but not yet invoiced, expected scope changes, cost to complete and impact on runway

The principle: update the numbers when contracts change, not just when invoices arrive.

7. When the spreadsheet stops being enough

With one or two simple CRO agreements, a well-kept spreadsheet works fine. Warning signs that you have outgrown it:

• Finance and R&D maintain separate contract trackers
• Approved change orders are not consistently reflected in contract totals
• Purchase orders are hard to reconcile with contracts
• Invoice approvals happen in email threads
• Board reporting requires manual consolidation every time
• Nobody is sure which version of the numbers is current

The problem is rarely a lack of expertise. It is that information belonging to the same process is spread across disconnected tools.

How biosuite helps

biosuite connects supplier contracts, change orders, purchase orders and invoices for small biotech teams, so committed, invoiced and remaining spend are visible in one place, alongside your existing accounting system. The starter plan is free.

Start tracking your CRO commitments for free →

Frequently asked questions

How do you track CRO contract spend?

Record the value of each SOW, add approved change orders, link purchase orders to the underlying contract and check invoices against both. Track proposed change orders separately as potential exposure.

What is a CRO change order?

A documented change to the agreed scope, price or timeline of a CRO engagement. Most contracts require formal approval before a change order takes effect.

How do you calculate remaining CRO contract value?

Remaining contract value = original contract value + approved change orders − invoiced amount. Adjust for credit notes and cancellations, and compare amounts on a consistent basis (e.g. excluding VAT).

Are CRO commitments the same as accruals?

No. A commitment is what you have agreed to pay under a contract. An accrual is the cost of work already performed but not yet invoiced.

Does a small biotech need procurement software?

Not always. With a few simple agreements, a spreadsheet can work. Dedicated software becomes valuable when change orders, POs and invoice reviews become hard to keep consistent across teams.

Reference: Getz K, Smith Z, Botto E, Murphy E, Dauchy A. (2024). New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance. Therapeutic Innovation & Regulatory Science, 58, 539–548. DOI: 10.1007/s43441-024-00622-9

The examples in this article are illustrative and do not constitute legal, accounting or financial advice.